Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Prof. Andrew J.S Coats
Anaemia has been found to affect nearly a quarter of heart failure patients. It is associated with a worse prognosis, an increased risk of hospitalisation and reduced exercise tolerance. Although the mechanism is unclear early reports suggest there may be some benefit to correction of anaemia by erythropoietin therapy. We await the outcomes of randomised controlled trials to know if this line of treatment is effective.
Chronic heart failure (CHF) is a multi-organ syndrome with changes in the periphery affecting muscle and blood vessels, neurohormonal activation and metabolic and hormonal changes. It is now recognised that anaemia is also frequently part of this syndrome.
If we define anaemia as a haemoglobin (Hb), less than 12.0 g/dl anaemia affects between 10-25% of CHF patients with more in the sicker patients’ population. The cause of anaemia in chronic heart failure is not known. In many cases anaemia in chronic failure shows similarities to the anaemia of chronic disorders, in which there is a defect in iron utilisation. The commonly recognised causes of anaemia in a general population such as iron, folate or B12 deficiency can exist in CHF and should be looked for. Blood loss can also be excessive in patients on anti-platelet and/or anticoagulant regimes for their primary cardiovascular disorder. In most CHF cases with anaemia, however, there is no identifiable cause. Aetiological factors are thought to include bone marrow dysfunction secondary to poor perfusion, impaired renal function and the effects of cytokine activation -especially TNF-alpha- which can induce both reduced erythropoietin production and increased resistance to its effects. In severe heart failure immune activation and pro-inflammatory cytokines correlate strongly with the severity of anaemia.
Anaemia has an independent effect on exercise intolerance by further reducing an already impaired oxygen delivery to the exercising muscle groups. Studies in large heart failure populations including cohorts from several of the large outcome trials in CHF have shown an independent detrimental effect of anaemia on the risk of death or admission to hospital for worsening heart failure. These findings suggest that treatment of anaemia might have the potential to improve outcomes.
Where an identifiable cause of anaemia in chronic heart failure is found it should be treated appropriately. We know that both erythropoietin or IV Iron treatment can increase haemoglobin levels in CHF and in early reports this has been associated with improved well-being and exercise tolerance. Whether this is with an acceptable safety profile and indeed whether it reduces the risk of mortality and morbidity is presently unknown. This exciting new treatment option awaits proper randomised outcome trials in the next few years.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Wexler D, Silverberg D, Sheps D, Blum M, Keren G, Iaina A, Schwartz D. Prevalence of anemia in patients admitted to hospital with a primary diagnosis of congestive heart failure. Int J Cardiol. 2004 Jul;96(1):79-87. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15203265&query_hl=1 2. Sharma R, Francis DP, Pitt B, Poole-Wilson PA, Coats AJ, Anker SD. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J. 2004 Jun;25(12):1021-8 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15191772&query_hl=4 3. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003 Jan 21;107(2):294-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14531773&query_hl=6 4. Mix TC, Brenner RM, Cooper ME, at al. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar;149(3):408-13 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.